Dapivirine/Maraviroc

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDapivirine/Maraviroc
Drug Alias NameDapivirine+MaravirocMaraviroc+DapivirineDapivirine and MaravirocMaraviroc and DapivirineMaraviroc/Dapivirine
ClassificationSmall molecules
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsC-C chemokine receptor type 5 antagonists
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseC-C chemokine receptor type 5
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes DapivirineMaraviroc
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMicrobicide Trials NetworkInternational Partnership For Microbicides Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInternational Partnership For Microbicides Inc
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A